Match!
Richard J. Wenstrup
Myriad Genetics
CancerMolecular biologyGeneticsMedicineBiology
135Publications
40H-index
7,549Citations
What is this?
Publications 136
Newest
#1Gregory Idos (SC: University of Southern California)H-Index: 13
#2Allison W. Kurian (Stanford University)H-Index: 37
Last. Stephen B. Gruber (SC: University of Southern California)H-Index: 64
view all 29 authors...
PurposeMultiplex gene panel testing (MGPT) allows for the simultaneous analysis of germline cancer susceptibility genes. This study describes the diagnostic yield and patient experiences of MGPT in diverse populations.Patients and MethodsThis multicenter, prospective cohort study enrolled participants from three cancer genetics clinics—University of Southern California Norris Comprehensive Cancer Center, Los Angeles County and University of Southern California Medical Center, and Stanford Cancer...
1 CitationsSource
#1Fransiska MalfaitH-Index: 35
#2Richard J. WenstrupH-Index: 40
Last. A. De PaepeH-Index: 81
view all 3 authors...
2 Citations
#1Melinda L. Telli (Stanford University)H-Index: 28
#2O Metzger (Harvard University)H-Index: 4
Last. Mehra Golshan (Brigham and Women's Hospital)H-Index: 32
view all 19 authors...
519Background: HRD status is significantly associated with a higher rate of response to neoadjuvant platinum-based therapy and improved PFS following adjuvant doxorubicin and cyclophosphamide (AC) in TNBC. We assessed the prognostic and predictive role of the HRD assay for platinum and PARP inhibitor response in BrighTNess. Methods: 634 stage II-III TNBC pts were randomized 2:1:1 to: Arm A: Paclitaxel (T) q wk x 12 + carboplatin (P) (AUC 6) q3 wk x 4 + veliparib (TPV) - > AC q2-3 wk x 4; Arm B: ...
5 CitationsSource
#1Melinda L. Telli (Stanford University)H-Index: 28
#2Jessica A. Hellyer (Stanford University)H-Index: 4
Last. James M. Ford (Stanford University)H-Index: 69
view all 18 authors...
Purpose Defects in the homologous recombination (HR) DNA repair pathway sensitize tumors to therapeutics that target this pathway. A significant proportion of triple-negative breast cancers (TNBC) carry HR defects. The HRD assay is highly associated with sensitivity to neoadjuvant platinum-based chemotherapy in TNBC. Standard chemotherapy consists of some combination of an anthracycline, cyclophosphamide, and taxane. This study assesses the association of HR deficiency status with response to st...
17 CitationsSource
#1Elisha HughesH-Index: 8
#2Thaddeus JudkinsH-Index: 10
Last. Alexander GutinH-Index: 30
view all 7 authors...
Background: Unaffected women with a strong family history of breast cancer (BC) are often referred for hereditary cancer testing with multi-gene panels; however, typically Methods: This IRB-approved study includes women of European ancestry tested with a multi-gene hereditary cancer panel who were negative for mutations in 11 genes associated with BC (BRCA1, BRCA2, TP53, PTEN, STK11, CDH1, PALB2, CHEK2, ATM, NBN, BARD1). Clinical information was collected from provider-completed test request for...
1 CitationsSource
#1Daniel G. LubaH-Index: 3
#2James A. DiSarioH-Index: 34
Last. Sapna Syngal (Brigham and Women's Hospital)H-Index: 58
view all 17 authors...
Background & Aims Lynch syndrome is a genetic disorder that greatly increases risk for colorectal and other cancers, although it is underdiagnosed. Prediction of MLH1 , MSH2 , and MSH6 (PREMM 1,2,6 ) is a web-based tool that analyzes individuals' personal/family histories of cancer to quantify their likelihood of carrying a germline mutation associated with Lynch syndrome. We investigated the feasibility of systematic risk assessment for Lynch syndrome in a community gastroenterology practice us...
4 CitationsSource
#1Kari G. Chaffee (Mayo Clinic)H-Index: 19
#2Ann L. Oberg (Mayo Clinic)H-Index: 55
Last. Gloria M. Petersen (Mayo Clinic)H-Index: 91
view all 10 authors...
Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history
16 CitationsSource
#1Priyanka Sharma (KU: University of Kansas)H-Index: 19
#2William E. BarlowH-Index: 64
Last. Daniel F. Hayes (UM: University of Michigan)H-Index: 106
view all 13 authors...
9 CitationsSource
#1Jennifer S. Ko (Cleveland Clinic)H-Index: 15
#2Balwir Matharoo-Ball (University of Nottingham)H-Index: 14
Last. Loren E. ClarkeH-Index: 16
view all 19 authors...
Background: Histopathologic examination alone can be inadequate for diagnosis of certain melanocytic neoplasms. Recently, a 23-gene expression signature was clinically validated as an ancillary diagnostic test to differentiate benign nevi from melanoma. The current study assessed the performance of this test in an independent cohort of melanocytic lesions against clinically proven outcomes. Methods: Archival tissue from primary cutaneous melanomas and melanocytic nevi was obtained from four inde...
10 CitationsSource
#1Elisha Hughes (Myriad Genetics)H-Index: 8
#2Thaddeus Judkins (Myriad Genetics)H-Index: 10
Last. Alexander Gutin (Myriad Genetics)H-Index: 30
view all 6 authors...
1579Background: Women who are unaffected with cancer but have a significant family history of breast cancer (BC) are frequently referred for hereditary cancer testing with multi-gene panels; however, < 10% test positive for clinically actionable mutations. Large-scale genotyping studies have identified common variants (primarily single-nucleotide polymorphisms) that individually confer modest BC risk, but together may explain the genetic susceptibility for BC in many women without monogenic muta...
2 CitationsSource
12345678910